Joincare Pharmaceutical Group Industry Co.,Ltd. (SWX:JCARE)

SWX:JCARE Income Statement

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Operating Revenue	15,148	15,492	16,522	17,013	15,747	13,446
Other Revenue	134.85	127.91	124.63	130.02	157.06	75.73
Revenue	15,283	15,619	16,646	17,143	15,904	13,522
Revenue Growth (YoY)	-5.43%	-6.17%	-2.90%	7.79%	17.62%	12.87%
Cost of Revenue	5,995	6,099	6,608	6,380	5,778	4,944
Gross Profit	9,288	9,521	10,039	10,763	10,126	8,577
Selling, General & Admin	4,733	4,836	5,368	5,944	5,966	4,898
Research & Development	1,332	1,435	1,662	1,742	1,397	1,072
Other Operating Expenses	214.48	155.49	177.21	196.72	180.8	161.03
Operating Expenses	6,283	6,431	7,224	7,885	7,553	6,136
Operating Income	3,005	3,090	2,815	2,877	2,572	2,442
Interest Expense	-96.53	-123.26	-146.73	-139.02	-90.28	-35.69
Interest & Investment Income	544.5	481.67	611.73	451.45	263.85	385.8
Currency Exchange Gain (Loss)	35.86	22.87	27.25	104.46	-2.74	-62.35
Other Non Operating Income (Expenses)	-11.49	-17.81	-7.69	-9.62	-4.89	-7.72
EBT Excluding Unusual Items	3,477	3,453	3,300	3,285	2,738	2,722
Gain (Loss) on Sale of Investments	-4.62	-17.5	-25.42	-76.26	-23.51	10.22
Gain (Loss) on Sale of Assets	45.19	45.26	-0.17	-0.71	24.04	-7.19
Asset Writedown	-30.81	-30.09	-3.27	-31.51	-8.25	-4.18
Other Unusual Items	178.82	123.81	194.75	280.06	221.66	229.61
Pretax Income	3,666	3,575	3,466	3,456	2,952	2,950
Income Tax Expense	615.35	592.14	614.54	561.8	339.48	371.69
Earnings From Continuing Operations	3,050	2,983	2,851	2,894	2,613	2,578
Minority Interest in Earnings	-1,655	-1,596	-1,408	-1,392	-1,284	-1,458
Net Income	1,395	1,387	1,443	1,503	1,328	1,120
Net Income to Common	1,395	1,387	1,443	1,503	1,328	1,120
Net Income Growth	-0.62%	-3.90%	-3.99%	13.12%	18.57%	25.28%
Shares Outstanding (Basic)	1,862	1,874	1,898	1,894	1,935	1,948
Shares Outstanding (Diluted)	1,862	1,874	1,898	1,897	1,937	1,956
Shares Change (YoY)	-0.23%	-1.30%	0.07%	-2.07%	-0.97%	0.76%
EPS (Basic)	0.75	0.74	0.76	0.79	0.69	0.58
EPS (Diluted)	0.75	0.74	0.76	0.79	0.69	0.57
EPS Growth	-0.39%	-2.63%	-4.06%	15.52%	19.73%	24.33%
Free Cash Flow	2,892	2,657	2,799	2,830	1,042	2,195
Free Cash Flow Per Share	1.55	1.42	1.47	1.49	0.54	1.12
Dividend Per Share	0.200	0.200	0.180	0.180	0.150	0.150
Dividend Growth	11.11%	11.11%	-	20.00%	-	-6.25%
Gross Margin	60.77%	60.96%	60.31%	62.78%	63.67%	63.43%
Operating Margin	19.66%	19.78%	16.91%	16.78%	16.18%	18.06%
Profit Margin	9.13%	8.88%	8.67%	8.77%	8.35%	8.29%
Free Cash Flow Margin	18.93%	17.01%	16.81%	16.51%	6.55%	16.23%
EBITDA	3,798	3,866	3,837	3,683	3,167	2,989
EBITDA Margin	24.85%	24.75%	23.05%	21.48%	19.91%	22.10%
D&A For EBITDA	792.84	775.67	1,022	805.34	594.45	546.91
EBIT	3,005	3,090	2,815	2,877	2,572	2,442
EBIT Margin	19.66%	19.78%	16.91%	16.78%	16.18%	18.06%
Effective Tax Rate	16.79%	16.56%	17.73%	16.25%	11.50%	12.60%
Revenue as Reported	15,283	15,619	16,646	17,143	15,904	13,522

Source: S&P Global Market Intelligence. Standard template. Financial Sources.